Compare Chipotle Mexican Grill, Inc. (CMG) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chipotle Mexican Grill, Inc. vs Crispr Therapeutics AG — how do they compare? Chipotle Mexican Grill, Inc. trades at $32.63 (market cap $41.30B), while Crispr Therapeutics AG trades at $54.09 (market cap $5.22B). The key difference: Chipotle Mexican Grill, Inc. is far larger — about 7.9× Crispr Therapeutics AG's market cap. Which is the better fit depends on your goals.
| CMG | CRSP | |
|---|---|---|
Market Cap | $41.30B | $5.22B |
Sector | Consumer Cyclical | Health |
52-Week High | $44.04 | $76.78 |
52-Week Low | $28.17 | $44.34 |
Enterprise Value | $46.05B | $3.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CMG trades at $32.62, up 1.99% today, with a bearish technical signal from moving averages but oversold RSI levels. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.33 actual vs. $0.32 expected, and continues expansion into Saudi Arabia. Revenue grew to $11.93B in 2025, though net income margin dipped to 11.42% from 13.55% in 2024.
Outlook remains positive with a $42.17 consensus price target and 70% buy ratings, but risks include food safety concerns from recent salmonella and cyclospora outbreaks, margin compression, and negative net cash flow trends. International growth and buybacks support upside, yet consumer caution and cost pressures pose headwinds.
CRISPR Therapeutics (CRSP) trades at $53.99, down 0.15% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by 151% YoY growth in CASGEVY sales to $76 million. Financials show deep losses with a net income margin of -4,101.26% in 2025, though cash flow improved to a net positive $49.30M. Recent news highlights strong analyst optimism and pipeline advancements.
Outlook remains speculative with high growth potential from gene-editing therapies like CASGEVY, but significant risks persist from ongoing losses and clinical trial outcomes. Wall Street consensus is bullish with a $82.67 price target, implying 53% upside, though investors face volatility from earnings misses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
